The safety of SSRIs in generalised anxiety disorder: Any reason to be anxious?

Expert Opinion on Drug Safety

Volumn 2, Issue 5, 2003, Pages 485-493

  Masand, Prakash S ^a   Gupta, Sanjay ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Olean General Hospital   (United States)

Author keywords

generalised anxiety disorder (GAD); paroxetine; selective serotonin re uptake inhibitors (SSRIs)

Indexed keywords

BUSPIRONE; CYCLOHEXANOL DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; HUMAN; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BUSPIRONE; CLINICAL TRIALS; CYCLOHEXANOLS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 2142725959     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.5.485     Document Type: Review

References (50)

1. CULPEPPER L: Generalized anxiety disorder in primary care: emerging issues in management and treatment. J. Clin. Psychiatry (2002) 63(Suppl. 11):35-42. (Pubitemid 34535255)
2. WITTCHEN HU, HOYER J: Generalized anxiety disorder: nature and course. J. Clin. Psychiatry (2001) 62(Suppl. 11):15-19.
3. DAVIDSON JR: Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry (2001) 62(Suppl. 11):46-50.
4. GORMAN JM: Treatment of generalized anxiety disorder. J. Clin. Psychiatry (2002) 63(Suppl. 8):17-23. (Pubitemid 34535253)
5. SRAMEK J, ZAROTSKY V, CUTLER N: Generalized anxiety disorder: treatment options. Drugs (2002) 62(11):1635-1648. (Pubitemid 34848371)
6. ROBINS LN, REIGER DA: Psychiatric disorders in America: the Epidemiologic Catchment Area Study. The Free Press, New York (1991).
7. HALES RE, HILTY DA, WISE MG: A treatment algorithm for the management of anxiety in primary care practice. J. Clin. Psychiatry (1997) 58(Suppl. 3):76-80. (Pubitemid 27176256)
8. RICKELS, SCHWEIZER E: The clinical course and long-term management of generalized anxiety disorder. J. Clin. Psychopharmacol. (1990) 10(Suppl. 3):S101-S110.
9. BORKOVEC TD, RUSCIO AM: Psychotherapy for generalized anxiety disorder. J. Clin. Psychiatry (2001) 62(Suppl. 11):37-42.
10. LYDIARD RB: An overview of generalized anxiety disorder: disease state-appropriate therapy. Clin. Ther. (2000) 22(Suppl. A):A3-A19.
11. DAVIDSON JR, DUPONT RL, HEDGES D, HASKINS JT: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry (1999) 60(8):528-535. (Pubitemid 29413473)
12. ZOHAR J, WESTENBERG HGM: Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. Suppl. (2000) 403:39-49.
13. MULLER MJ, DRAGICEVIC A, FRIC M et al.: Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry (2003) 36(3):98-104. (Pubitemid 36791784)
14. LIVINGSTON MG, LIVINGSTON HM: Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf. (1996) 14(4):219-227. (Pubitemid 26128811)
15. GORMAN JM: The use of newer antidepressants for panic disorder. J. Clin. Psychiatry (1997) 58(Suppl. 14):54-58. (Pubitemid 28027660)
16. MASAND PS, GUPTA S: Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatry (1999) 7(2):69-84. (Pubitemid 29426569)
17. MASAND PS, GUPTA S: Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann. Clin. Psychiatry (2002) 14(3):175-182. (Pubitemid 36172566)
18. BUCKLEY N, MCMANUS PR: Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br. Med. J. (2002) 325(7376):1332-1333. (Pubitemid 35471550)
19. SARKO J: Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg. Med. Clin. North Am. (2000) 18(4):637-654.
20. SPINA E, SCORDO MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 19(4):299-320. (Pubitemid 34686722)
21. HEMERYCK A, BELPAIRE FM: Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr. Drug Metab. (2002) 3(1):13-37. (Pubitemid 34296308)
22. CLAYTON AH, PRADKO JF, CROFT HA: Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry (2002) 63(4):357-366. (Pubitemid 34456365)
23. KELTNER NL, MCAFEE KM, TAYLOR CL: Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect. Psychiatr. Care (2002) 38(3):111-116.
24. KANALY KA, BERMAN JR: Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. Curr. Womens Health Rep. (2002) 2(6):409-416.
25. STEIN DJ, STEIN MB, GOODWIN W, KUMAR R, HUNTER B: The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl.) (2001) 158(3):267-272. (Pubitemid 33071164)
26. POLLACK MH, ZANINELLI R, GODDARD A et al.: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry (2001) 62(5):350-357. (Pubitemid 32545557)
27. RICKELS K, ZANINELLI R, MCCAFFERTY J: Paroxetine treatment of GAD: a double-blind, placebo-controlled trial. Am. J. Psychiatry (2003) 160(4):749-756. (Pubitemid 41079609)
28. STOCCHI F, NORDERA G, JOKINEN RH et al.: PAROXETINE GENERALIZED ANXIETY DISORDER STUDY TEAM: Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry (2003) 64(3):250-258. (Pubitemid 36457322)
29. PAXIL PACKAGE INSERT: GlaxoSmithKline (2003).
30. BOYER WF, BLUMHARDT CL: The safety profile of paroxetine. J. Clin. Psychiatry (1992) 53(Suppl.):61-66.
31. HICKS JA, ARGYROPOULOS SV, RICH AS et al.: Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br. J. Psychiatry (2002) 180:528-535. (Pubitemid 34596804)
32. CHAVIRA DA, STEIN MB: Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder. J. Child Adolesc. Psychopharmacol. (2002) 12(1):47-54. (Pubitemid 34461533)
33. HEIKKINEN T, EKBLAD U, KERO P, EKBLAD S, LAINE K: Citalopram in pregnancy and lactation. Clin. Pharmacol. Ther. (2002) 72(2):184-191. (Pubitemid 35034496)
34. KORAN LM, BULLOCK KD, HARTSTON HJ, ELLIOTT MA, D'ANDREA V: Citalopram treatment of compulsive shopping: an open-label study. J. Clin. Psychiatry (2002) 63(8):704-708.
35. SEEDAT S, STEIN DJ, ZIERVOGEL C et al.: Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J. Child Adolesc. Psychopharmacol. (2002) 12(1):37-46. (Pubitemid 34461532)
36. VARIA I, RAUSCHER F: Treatment of generalized anxiety disorder with citalopram. Int. Clin. Psychopharmacol. (2002) 17(3):103-107. (Pubitemid 34442190)
37. VARIA I, CLOUTIER C, DORAISWAMY PM: Treatment of social anxiety disorder with citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(1):205-208. (Pubitemid 34045170)
38. MORK A, KREILGAARD M, SANCHEZ C: The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology (2003) 45(2):167-173. (Pubitemid 36782529)
39. STAHL S, GERGEL I, LI D: Escitalopram in the treatment of panic disorder. CINP (2002) Poster 4.W.072.
40. KASPER S, LOFT H, SMITH JR: Escitalopram is efficacious and well-tolerated in the treatment of SAD. CINP (2002) Poster 2.W.062.
41. DAVIDSON J, BOSE A, SU G: Escitalopram in the treatment of generalized anxiety disorder. CINP (2002) Poster 4.W.059.
42. MACQUEEN G, BORN L, STEINER M: The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. (2001) 7(1):1-24. (Pubitemid 32280681)
43. DAVIDSON JR, ROTHBAUM BO, VAN DER KOLK BA, SIKES CR, FARFEL GM: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry (2001) 58(5):485-492. (Pubitemid 32411330)
44. ALLGULANDER C, DAHL AA, MORRIS PL et al.: Sertraline for the treatment of generalized anxiety disorder: results of a multicenter double-blind placebo-controlled trial. 41st Annual Meeting of ACNP, San Jan, Puerto Rico (2002) 123.
45. BRAWMAN-MINTZER O, RICKELS K, RYNN M, PALESH Y, HEBERT R, KNAPP R: Sertraline in the treatment of generalized anxiety disorder: results and predictors of response. 41st Annual Meeting of ACNP, San Jan, Puerto Rico (2002) 122.
46. RYNN MA, SIQUELAND L, RICKELS K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am. J. Psychiatry (2001) 158(12):2008-2014. (Pubitemid 33104106)
47. SHEEHAN DV: Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J. Clin. Psychiatry (1999) 60(Suppl. 22):23-28. (Pubitemid 30107952)
48. ALLGULANDER C, HACKETT D, SALINAS E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry (2001) 179:15-22.
49. MEONI P, SALINAS E, BRAULT Y, HACKETT D: Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J. Clin. Psychiatry (2001) 62(11):888-893. (Pubitemid 33131176)
50. KUNZ N, KHAN A, NICOLACOPOULOS E, JENKINS L, YEUNG PP: Venlafaxine extended release for the treatment of children and adolescents with generalized anxiety disorder. CINP (2002) Poster 3.W.006.